• Pol II Degradation Drives Cell Death Independent of Transcri

  2026-04-12

  A recent preprint reveals that targeted degradation of RNA polymerase II (Pol II) initiates cell death in tumor cells, independent of transcriptional inhibition. This finding uncouples apoptosis induction from transcriptional loss, reshaping our understanding of regulated cell death and informing new strategies for cancer research.

• AMD-070 Hydrochloride: Workflow Enhancements for CXCR4 Antag

  2026-04-12

  AMD-070 hydrochloride (Mavorixafor hydrochloride) is redefining CXCR4 antagonist workflows with its oral bioavailability, high solubility, and validated clinical impact in rare immunodeficiencies. Learn how to incorporate this compound for superior reproducibility in cell migration, anti-HIV, and immune modulation studies, plus troubleshooting tips for optimal results.

• Simvastatin (Zocor): Applied Workflows in Cancer & Lipid Res

  2026-04-11

  Simvastatin (Zocor) from APExBIO is more than a cholesterol-lowering agent—its precise inhibition of HMG-CoA reductase and apoptosis-inducing effects enable advanced research into hyperlipidemia and hepatic cancer. This article translates machine learning–driven phenotypic insights into actionable protocols, empowering bench scientists to optimize their experimental strategies.

• Live-Dead Cell Staining Kit: Dual Calcein-AM PI Workflow Gui

  2026-04-11

  The Live-Dead Cell Staining Kit enables rapid, fluorescence-based discrimination of viable and non-viable cells using Calcein-AM and Propidium Iodide. It is optimized for applications like cell viability assays, flow cytometry, and cytotoxicity studies, but is not intended for diagnostic or clinical use. Researchers should follow recommended storage and handling to ensure robust results.

• Pimozide as a Dopamine Receptor Inhibitor in Neuroscience Re

  2026-04-10

  Pimozide is a potent neuroleptic dopamine receptor inhibitor widely used to modulate dopaminergic neurotransmission in models of neurological and psychiatric disorders. It is particularly applicable in studies requiring selective inhibition of D2, D3, and D4 receptors, such as those focusing on schizophrenia, Parkinson’s disease, or Tourette’s syndrome. Pimozide should not be used in workflows requiring water or ethanol solubility or long-term solution storage due to its solubility and stability limitations.

• Merimepodib (VX-497): Advanced IMPDH Inhibitor for Transl...

  2026-04-10

  Merimepodib (VX-497) stands out as a selective, orally bioavailable IMPDH inhibitor, enabling precise manipulation of guanine nucleotide biosynthesis in cancer, immunology, and virology research. With robust antiviral and immunosuppressive efficacy, it empowers researchers to probe cellular metabolism, viral replication, and immune modulation with unmatched specificity and reproducibility.

• Merimepodib (VX-497): Unlocking IMPDH Inhibition for Next...

  2026-04-09

  Explore Merimepodib (VX-497), a potent oral IMPDH inhibitor, and its unique capacity to reshape cancer, immunology, and antiviral research. Discover how IMPDH pathway inhibition enables advanced targeting of nucleotide metabolism for therapeutic innovation.

• BML-277: Potent and Selective Chk2 Inhibitor for DNA Dama...

  2026-04-08

  BML-277 redefines the standard for ATP-competitive Chk2 inhibition, empowering researchers to dissect DNA damage checkpoint pathways and radioprotect T-cells with precision. Its unmatched selectivity and nanomolar potency enable advanced workflows in cancer biology and genome stability studies, while its proven role in modulating cGAS signaling unlocks new insights into aging and tumorigenesis.

• Mavorixafor Hydrochloride: Redefining CXCR4 Antagonism fo...

  2026-04-08

  This thought-leadership article explores the mechanistic basis and strategic implications of Mavorixafor hydrochloride (AMD-070 hydrochloride) as a potent, selective CXCR4 antagonist. It provides translational researchers with actionable insight into the inhibition of the CXCR4/CXCL12 signaling axis, its transformative role in immune cell trafficking, and its impact on emerging therapies for WHIM syndrome, Waldenström's Macroglobulinemia, and HIV infection. Integrating recent scientific evidence and cross-referencing related resources, the article highlights experimental best practices, competitive differentiators, and a forward-looking vision for CXCR4-targeted drug development.

• Live-Dead Cell Staining Kit: Precision Cell Viability Ass...

  2026-04-07

  The APExBIO Live-Dead Cell Staining Kit leverages Calcein-AM and Propidium Iodide dual staining to deliver rapid, quantitative, and highly discriminative cell viability analysis. This advanced workflow supports robust applications in drug cytotoxicity, biomaterial evaluation, and apoptosis research—surpassing traditional methods in both accuracy and reproducibility.

• Fingolimod (FTY720): S1P Receptor Modulator for Advanced ...

  2026-04-07

  Fingolimod (FTY720) is revolutionizing both multiple sclerosis research and next-generation immunoengineering by acting as a potent S1P receptor modulator. Explore optimized workflows, troubleshooting strategies, and applied use-cases that leverage its unique dual action on immune cell trafficking and neuroprotection. Discover why APExBIO's Fingolimod (FTY720) is the trusted choice for reproducible, high-impact experimental results.

• Fingolimod (FTY720): Next-Gen S1P Modulation for Neuroimm...

  2026-04-06

  Explore the emerging role of Fingolimod (FTY720) as a sphingosine-1-phosphate receptor agonist in advanced neuroimmune engineering. This article delves into its precise mechanism, innovative applications in immune cell manipulation, and unique neuroprotective effects, setting it apart from existing literature.

• Heparin Sodium: Advanced Mechanisms and Emerging Delivery...

  2026-04-06

  Explore the multifaceted role of Heparin sodium as a glycosaminoglycan anticoagulant for thrombosis research, including its molecular mechanism, pharmacokinetics, and innovative oral delivery via polymeric nanoparticles. This article offers new insights linking anticoagulant drug research with the latest advances in nanoparticle-mediated delivery and cell biology.

• Redefining Translational Horizons: Merimepodib (VX-497) a...

  2026-04-05

  Merimepodib (VX-497), a potent, selective, noncompetitive, and orally bioavailable IMPDH inhibitor, is at the vanguard of translational research targeting guanine nucleotide biosynthesis. This thought-leadership article synthesizes mechanistic insight, recent virology breakthroughs, and actionable guidance for researchers seeking to leverage IMPDH inhibition across cancer chemotherapy, immune modulation, and antiviral drug development. Integrating new evidence on host-pathogen interactions and referencing pivotal work on viral metabolic rewiring, we present Merimepodib as a transformative tool for unlocking next-generation therapeutic strategies. This piece not only contextualizes APExBIO’s Merimepodib within the competitive landscape but also charts unexplored territory for translational application, offering differentiated value beyond conventional product pages.

• Heparin Sodium: Applied Anticoagulant Workflows & Innovat...

  2026-04-04

  Heparin sodium from APExBIO sets the benchmark for anticoagulant research, empowering robust anti-factor Xa and aPTT assays as well as advanced delivery explorations. This article details practical workflows, troubleshooting strategies, and the integration of heparin sodium in cutting-edge thrombosis and nanoparticle research.

16528 records 1/1102 page Next 12345 下5页 Last page